Table 2.
Characteristics of phase II and III trials of TKIs in ovarian cancer.
| Study | Year | Stage | Targeting agent | Setting |
|---|---|---|---|---|
| AG02.11 | 2012 | Phase II | Sunitinib | Recurrent platinum-resistant |
| OVAR 16 | 2014 | Phase III | Pazopanib | Front-line and maintenance |
| MITO 11 | 2015 | Phase II | Pazopanib plus weekly paclitaxel | Platinum-resistant or platinum-refractory |
| OVAR 12 | 2016 | Phase III | First-line chemotherapy with or without nintedanib | Front-line and maintenance |
| ICON6 | 2016 | Phase III | Cediranib | Recurrent platinum-sensitive |
| TRIAS | 2018 | Phase II | Sorafenib plus topotecan | Recurrent platinum-resistant |
| PAZOFOS | 2020 | Phase II | Pazopanib and fosbretabulin | Recurrent |
| NCT01610206 | 2020 | Phase II | Weekly gemcitabine plus pazopanib | Persistent or recurrent |
| NCT01610869 | 2020 | Phase II | Cyclophosphamide and nintedanib | Recurrent |
| REGOVAR | 2022 | Phase II | Regorafenib or tamoxifen | Recurrent platinum-sensitive |
| NCT00710762 | 2011 | Phase II | Nintedanib | Recurrent |